Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 2, 2005, Pages 256-263

  Nielsen, Aiqun ^a   Scarlett, Christopher J ^a   Samra, Jaswinder S ^a   Gill, Anthony ^b   Li, Yong ^c   Allen, Barry J ^c   Smith, Ross C ^a,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Pancreatic cancer; Real time quantitative reverse transcription polymerase chain reaction; Urokinase type plasminogen activator

Indexed keywords

MESSENGER RNA; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CYSTADENOCARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE BINDING; METASTASIS POTENTIAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR LOCALIZATION;

EID: 14844304638     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03531.x     Document Type: Article

References (36)

1. Tarbe N, Losch S, Burtscher H, Jarsch M, Weidle UH. Identification of rat pancreatic carcinoma genes associated with lymphogenous metastasis. Anticancer Res. 2002; 22: 2015-27.
2. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 2000; 57: 25-40.
3. Cantero D, Friess H, Deflorin J et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br. J. Cancer 1997; 75: 388-95.
4. Ahmed N, Oliva K, Wang Y, Quin M. Rice G. Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach. Proteomics 2003; 3: 288-98.
5. Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 1992; 11: 291-311.
6. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 2003; 160: 781-91.
7. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997; 72: 1-22.
8. Zemzoum I, Kates RE, Ross JS et al. Invasion factors uPA/ PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J. Clin. Oncol 2003; 21: 1022-8.
9. Taniguchi T, Kakkar AK, Tuddenham EG, Williamson RC, Lemoi NR. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res. 1998; 58: 4461-7.
10. Tkachuk V, Stepanova V, Little PJ, Bobik A, Regulation and role of urokinase plasminogen activator in vascular remodelling. Clin. Exp. Pharmacol. Physiol. 1996; 23: 759-65.
11. Spyratos F, Bouchet C, Tozlu S et al. Prognostic value of uPA, PAI-1 and PAI-2 niRNA expression in primary breast cancer. Anticancer Res. 2002; 22: 2997-3004.
12. Rosenberg S. New developments in the urokinase-type plasminogen activator system. Expert Opin. Ther. Targets 2001; 5: 711-22.
13. Nielsen BS, Sehested M, Timshel S, Pyke C, Dano K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab. Invest. 1996; 74: 168-77.
14. Hsu DW, Efird JT, Hedley-Whyte ET. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am. J. Pathol 1995; 147: 114-23.
15. Verspaget HW, Sier CF, Ganesh S, Griffioen G, Lamers CB. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer [Review]. Eur. J. Cancer 1995; 31A: 1105-9.
16. 213Bi-labelled- plasminogen activator inhibitor type 2. Br. J. Cancer 2003; 88: 944-50.
17. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. Br. J. Cancer 2002; 86: 1197-203.
18. O'Mahony CA, Seidel A, Albo D, Chang H, Tuszynski GP, Berger DH. Angiostatin generation by human pancreatic cancer. J. Surg. Res. 1998; 77: 55-8.
19. Tsunoda T, Ura K, Eto T, Matsumoto T, Tsuchiya R. UICC and Japanese stage classifications for carcinoma of the pancreas. Int. J. Pancreatol. 1991; 8: 205-14.
20. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: 2002-7.
21. Rasmussen R. Quantification on the LightCycler. In: Meuer S, Wittwer C, Nakagawara K, eds. Rapid Cycle Real-Time PCR Methods and Applications. Heidelberg: Springer Press, 2001; 21-34.
22. Paciucci R, Vila MR, Adell T et al. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreatic tumor cells overexpressing met. Am. J. Pathol 1998; 153: 201-12.
23. Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L, Graeff H. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol. Chem. Hoppe-Seyler 1992; 373: 611-22.
24. Liang OD, Chavakis T, Linder M, Bdeir K, Kuo A, Preissnei KT. Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence. Biol. Chem. 2003; 384: 229-36.
25. Liu J, Chakraborty C, Graham CH, Barbin YP, Dixon SJ, Lala PK. Noncatalytic domain of uPA stimulates human extravillous trophoblast migration by using phospholipase C, phosphatidylinositol 3-kinase and mitogen-activated protein kinase. Exp. Cell Res. 2003; 286: 138-51.
26. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci. 2003; 94: 43-9.
27. Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer. Relationship to tumor pathology. Eur. J. Cancer 2003; 39: 981-8.
28. Pedersen AN, Mouridsen HT, Tenney DY, Brunner N. Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue. Eur. J. Cancer 2003; 39: 899-908.
29. Montuori N, Mattiello A, Mancini A et al. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma. Int. J. Cancer 2003; 105: 353-60.
30. Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U, Kocijancic B. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. Oncol. Rep. 2003; 10: 635-9.
31. Schneider J, Pollan M, Tejerina A, Sanchez J, Lucas AR. Accumulation of uPA-PAI-1 complexes inside the tumor cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer. Br. J. Cancer 2003; 88: 96-101.
32. Paciucci R, Tora M, Diaz VM, Real FX. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene 1998; 16: 625-33.
33. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM. TGF-β induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int. J. Cancer 2001; 93: 204-11.
34. Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am. J. Gastroenterol. 1993; 88: 1928-33.
35. Wang W, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 1999; 18: 4554-63.
36. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 2000; 25: 169-93.